Remote decentralized clinical trials: a new opportunity for laboratory medicine
The traditional venue of clinical trials has been hospitals or specialized research units, usually requiring participants to come on-site. Although their contribution to biomedical progress is beyond dispute, they are characterised by two crucial logistical and ultimately scientifical limitations: p...
Gespeichert in:
| Veröffentlicht in: | Clinical chemistry and laboratory medicine 2023-07, Vol.61 (8), p.1388-1394 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1394 |
|---|---|
| container_issue | 8 |
| container_start_page | 1388 |
| container_title | Clinical chemistry and laboratory medicine |
| container_volume | 61 |
| creator | Pennestrì, Federico Banfi, Giuseppe Tomaiuolo, Rossella |
| description | The traditional venue of clinical trials has been hospitals or specialized research units, usually requiring participants to come on-site. Although their contribution to biomedical progress is beyond dispute, they are characterised by two crucial logistical and ultimately scientifical limitations: poor retention and poor generalizability of results, as patients often have problems in concluding the investigation on-site. Remote Decentralised Clinical Trials (RDCTs) take advantage of digital technologies to design trial activities closer to the home of participants, with the aims of minimizing travel to health facilities and the risk of infections, improving the quality of life of participants and caregivers, reducing work absenteeism, including broader cohorts of patients and possibly reducing costs. RDCTs represent a minority of current global research, but the Covid-19 pandemic brought them to the fore. The authors of this paper promote the spread of RDCTs, building on early recommendations from international institutions, and provide some examples of their use and potential benefits in laboratory medicine. |
| doi_str_mv | 10.1515/cclm-2022-1184 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2760821110</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2831425958</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-c04877f3d3f2a6bd7f0aaa1cd9e92380a4c95a020229607a9c7182d361c4b8db3</originalsourceid><addsrcrecordid>eNptkE1L9TAQhYMofm_fpQTcuKlmkrRJBRcifoEgiK5DmqQSSZtrmiLXX2_r9VUQVzOLZ86ccxD6B-QYSihPjAldQQmlBYDka2gbOBMFZwzWP3deVBWFLbQzDC-EQFlysYm2WFXWohawje4fXBezw9YZ1-ekg393Fpvge290wDl5HYZTrHHv3nBcLGLKY-_zErcx4aCbmHSOaYk7Z73xvdtDG-104fa_5i56urp8vLgp7u6vby_O7wrDOcuFIVwK0TLLWqqrxoqWaK3B2NrVlEmiualLTeZgdUWEro0ASS2rwPBG2obtoqOV7iLF19ENWXV-MC4E3bs4DoqKikgKAGRCD3-hL3FM_eROUcmA07Iu5UQdryiT4jAk16pF8p1OSwVEzVWruWo1O1Jz1dPBwZfs2Ezpv_H_3U7A2Qp40yG7ZN1zGpfT8vP-b-UKJDAp2QePTY3U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2831425958</pqid></control><display><type>article</type><title>Remote decentralized clinical trials: a new opportunity for laboratory medicine</title><source>De Gruyter journals</source><creator>Pennestrì, Federico ; Banfi, Giuseppe ; Tomaiuolo, Rossella</creator><creatorcontrib>Pennestrì, Federico ; Banfi, Giuseppe ; Tomaiuolo, Rossella</creatorcontrib><description>The traditional venue of clinical trials has been hospitals or specialized research units, usually requiring participants to come on-site. Although their contribution to biomedical progress is beyond dispute, they are characterised by two crucial logistical and ultimately scientifical limitations: poor retention and poor generalizability of results, as patients often have problems in concluding the investigation on-site. Remote Decentralised Clinical Trials (RDCTs) take advantage of digital technologies to design trial activities closer to the home of participants, with the aims of minimizing travel to health facilities and the risk of infections, improving the quality of life of participants and caregivers, reducing work absenteeism, including broader cohorts of patients and possibly reducing costs. RDCTs represent a minority of current global research, but the Covid-19 pandemic brought them to the fore. The authors of this paper promote the spread of RDCTs, building on early recommendations from international institutions, and provide some examples of their use and potential benefits in laboratory medicine.</description><identifier>ISSN: 1434-6621</identifier><identifier>EISSN: 1437-4331</identifier><identifier>DOI: 10.1515/cclm-2022-1184</identifier><identifier>PMID: 36597971</identifier><language>eng</language><publisher>Germany: De Gruyter</publisher><subject>Absenteeism ; Clinical trials ; COVID-19 ; decentralized clinical trials ; digital medicine ; Health care facilities ; Health risks ; Hospital facilities ; Laboratories ; Onsite ; Pandemics ; patient-reported outcomes ; Patients ; Quality of life ; remote clinical trials ; Telemedicine ; value-based care</subject><ispartof>Clinical chemistry and laboratory medicine, 2023-07, Vol.61 (8), p.1388-1394</ispartof><rights>2022 Walter de Gruyter GmbH, Berlin/Boston.</rights><rights>2022 Walter de Gruyter GmbH, Berlin/Boston</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-c04877f3d3f2a6bd7f0aaa1cd9e92380a4c95a020229607a9c7182d361c4b8db3</citedby><cites>FETCH-LOGICAL-c443t-c04877f3d3f2a6bd7f0aaa1cd9e92380a4c95a020229607a9c7182d361c4b8db3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.degruyter.com/document/doi/10.1515/cclm-2022-1184/pdf$$EPDF$$P50$$Gwalterdegruyter$$H</linktopdf><linktohtml>$$Uhttps://www.degruyter.com/document/doi/10.1515/cclm-2022-1184/html$$EHTML$$P50$$Gwalterdegruyter$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,66497,68281</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36597971$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pennestrì, Federico</creatorcontrib><creatorcontrib>Banfi, Giuseppe</creatorcontrib><creatorcontrib>Tomaiuolo, Rossella</creatorcontrib><title>Remote decentralized clinical trials: a new opportunity for laboratory medicine</title><title>Clinical chemistry and laboratory medicine</title><addtitle>Clin Chem Lab Med</addtitle><description>The traditional venue of clinical trials has been hospitals or specialized research units, usually requiring participants to come on-site. Although their contribution to biomedical progress is beyond dispute, they are characterised by two crucial logistical and ultimately scientifical limitations: poor retention and poor generalizability of results, as patients often have problems in concluding the investigation on-site. Remote Decentralised Clinical Trials (RDCTs) take advantage of digital technologies to design trial activities closer to the home of participants, with the aims of minimizing travel to health facilities and the risk of infections, improving the quality of life of participants and caregivers, reducing work absenteeism, including broader cohorts of patients and possibly reducing costs. RDCTs represent a minority of current global research, but the Covid-19 pandemic brought them to the fore. The authors of this paper promote the spread of RDCTs, building on early recommendations from international institutions, and provide some examples of their use and potential benefits in laboratory medicine.</description><subject>Absenteeism</subject><subject>Clinical trials</subject><subject>COVID-19</subject><subject>decentralized clinical trials</subject><subject>digital medicine</subject><subject>Health care facilities</subject><subject>Health risks</subject><subject>Hospital facilities</subject><subject>Laboratories</subject><subject>Onsite</subject><subject>Pandemics</subject><subject>patient-reported outcomes</subject><subject>Patients</subject><subject>Quality of life</subject><subject>remote clinical trials</subject><subject>Telemedicine</subject><subject>value-based care</subject><issn>1434-6621</issn><issn>1437-4331</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNptkE1L9TAQhYMofm_fpQTcuKlmkrRJBRcifoEgiK5DmqQSSZtrmiLXX2_r9VUQVzOLZ86ccxD6B-QYSihPjAldQQmlBYDka2gbOBMFZwzWP3deVBWFLbQzDC-EQFlysYm2WFXWohawje4fXBezw9YZ1-ekg393Fpvge290wDl5HYZTrHHv3nBcLGLKY-_zErcx4aCbmHSOaYk7Z73xvdtDG-104fa_5i56urp8vLgp7u6vby_O7wrDOcuFIVwK0TLLWqqrxoqWaK3B2NrVlEmiualLTeZgdUWEro0ASS2rwPBG2obtoqOV7iLF19ENWXV-MC4E3bs4DoqKikgKAGRCD3-hL3FM_eROUcmA07Iu5UQdryiT4jAk16pF8p1OSwVEzVWruWo1O1Jz1dPBwZfs2Ezpv_H_3U7A2Qp40yG7ZN1zGpfT8vP-b-UKJDAp2QePTY3U</recordid><startdate>20230726</startdate><enddate>20230726</enddate><creator>Pennestrì, Federico</creator><creator>Banfi, Giuseppe</creator><creator>Tomaiuolo, Rossella</creator><general>De Gruyter</general><general>Walter De Gruyter & Company</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20230726</creationdate><title>Remote decentralized clinical trials: a new opportunity for laboratory medicine</title><author>Pennestrì, Federico ; Banfi, Giuseppe ; Tomaiuolo, Rossella</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-c04877f3d3f2a6bd7f0aaa1cd9e92380a4c95a020229607a9c7182d361c4b8db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Absenteeism</topic><topic>Clinical trials</topic><topic>COVID-19</topic><topic>decentralized clinical trials</topic><topic>digital medicine</topic><topic>Health care facilities</topic><topic>Health risks</topic><topic>Hospital facilities</topic><topic>Laboratories</topic><topic>Onsite</topic><topic>Pandemics</topic><topic>patient-reported outcomes</topic><topic>Patients</topic><topic>Quality of life</topic><topic>remote clinical trials</topic><topic>Telemedicine</topic><topic>value-based care</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pennestrì, Federico</creatorcontrib><creatorcontrib>Banfi, Giuseppe</creatorcontrib><creatorcontrib>Tomaiuolo, Rossella</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical chemistry and laboratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pennestrì, Federico</au><au>Banfi, Giuseppe</au><au>Tomaiuolo, Rossella</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Remote decentralized clinical trials: a new opportunity for laboratory medicine</atitle><jtitle>Clinical chemistry and laboratory medicine</jtitle><addtitle>Clin Chem Lab Med</addtitle><date>2023-07-26</date><risdate>2023</risdate><volume>61</volume><issue>8</issue><spage>1388</spage><epage>1394</epage><pages>1388-1394</pages><issn>1434-6621</issn><eissn>1437-4331</eissn><abstract>The traditional venue of clinical trials has been hospitals or specialized research units, usually requiring participants to come on-site. Although their contribution to biomedical progress is beyond dispute, they are characterised by two crucial logistical and ultimately scientifical limitations: poor retention and poor generalizability of results, as patients often have problems in concluding the investigation on-site. Remote Decentralised Clinical Trials (RDCTs) take advantage of digital technologies to design trial activities closer to the home of participants, with the aims of minimizing travel to health facilities and the risk of infections, improving the quality of life of participants and caregivers, reducing work absenteeism, including broader cohorts of patients and possibly reducing costs. RDCTs represent a minority of current global research, but the Covid-19 pandemic brought them to the fore. The authors of this paper promote the spread of RDCTs, building on early recommendations from international institutions, and provide some examples of their use and potential benefits in laboratory medicine.</abstract><cop>Germany</cop><pub>De Gruyter</pub><pmid>36597971</pmid><doi>10.1515/cclm-2022-1184</doi><tpages>07</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1434-6621 |
| ispartof | Clinical chemistry and laboratory medicine, 2023-07, Vol.61 (8), p.1388-1394 |
| issn | 1434-6621 1437-4331 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2760821110 |
| source | De Gruyter journals |
| subjects | Absenteeism Clinical trials COVID-19 decentralized clinical trials digital medicine Health care facilities Health risks Hospital facilities Laboratories Onsite Pandemics patient-reported outcomes Patients Quality of life remote clinical trials Telemedicine value-based care |
| title | Remote decentralized clinical trials: a new opportunity for laboratory medicine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T21%3A41%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Remote%20decentralized%20clinical%20trials:%20a%20new%20opportunity%20for%20laboratory%20medicine&rft.jtitle=Clinical%20chemistry%20and%20laboratory%20medicine&rft.au=Pennestr%C3%AC,%20Federico&rft.date=2023-07-26&rft.volume=61&rft.issue=8&rft.spage=1388&rft.epage=1394&rft.pages=1388-1394&rft.issn=1434-6621&rft.eissn=1437-4331&rft_id=info:doi/10.1515/cclm-2022-1184&rft_dat=%3Cproquest_cross%3E2831425958%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2831425958&rft_id=info:pmid/36597971&rfr_iscdi=true |